Cantor Fitzgerald Downgrades Ironwood Pharmaceuticals (IRWD) to Sell
Get Alerts IRWD Hot Sheet
Price: $4.31 +5.64%
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Cantor Fitzgerald's Irina Rivkind downgraded shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) from Hold to Sell following Q4 results Tuesday evening. Rivkind reduced her price target on the stock from $12 to $10.
The analyst cited valuation, pointing out profitability is not expected until 2017. Rivkind believes financing could be come an issue in 2013.
For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.
The analyst cited valuation, pointing out profitability is not expected until 2017. Rivkind believes financing could be come an issue in 2013.
For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
- Cisco rating cut at HSBC as analyst sees a lack of catalysts
Create E-mail Alert Related Categories
DowngradesRelated Entities
Cantor Fitzgerald, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share